Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2022-07-15 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
기타주요경영사항(자율공시)(전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Ensol Biosciences regarding the adjustment of the conversion price of convertible preferred shares due to a decline in market price. This type of disclosure relates to changes in capital structure and financial instruments, which falls under the 'Share Issue/Capital Change' category (SHA) as it directly impacts the number of convertible shares and the company's capital structure.
2022-07-15 Korean
기타주요경영사항(자율공시)(기술성평가 신청)
Regulatory Filings Classification · 100% confidence The document is a short, formal announcement regarding a 'Technology Assessment Application' for a KOSDAQ listing. It is a regulatory disclosure of a specific corporate event (filing for technical evaluation) rather than a full financial report, proxy, or meeting material. Given its nature as a specific regulatory disclosure that does not fit into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2022-06-10 Korean
증권발행결과(자율공시)(제3회차 CB)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) for a convertible bond (CB) issuance. It details the final issuance amount, payment date, and confirms the completion of the financing activity. This falls under the category of capital and financing updates.
2022-06-09 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) event held by Ensol Biosciences. It lists the date, time, location, participants, and agenda of the event. Since it is a brief notification regarding the occurrence of an IR event rather than the full presentation deck itself, and it fits the criteria for a regulatory announcement of an event, it is classified as a Regulatory Filing (RNS).
2022-06-07 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Correction of Convertible Bond Issuance' (전환사채권 발행결정 정정신고). It details changes to the issuance amount, investors, and terms of a previously announced convertible bond. In the context of Korean regulatory filings (DART), this is a standard disclosure for capital structure changes and financing activities. Since it relates to the issuance of debt instruments (convertible bonds) and updates to capital structure, it falls under the 'Capital/Financing Update' category.
2022-06-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) presentation. It specifies the date, time, location (online), and purpose of the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a standard corporate disclosure notice.
2022-05-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.